Abivax S.A.
- Stock
- Ticker ABVX
- ISIN US00370M1036
- Nasdaq
- US listing in dollars (ADR)
Performance, volatility and drawdowns of Abivax S.A. since 10/2023, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $72,118. Global equities (VT): $15,235.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −67.5% in 04/2025, measured from the peak in 04/2024. It took 15 months to get back to the old peak.
Financial statements
Amounts in € millions from the company's annual financial reports, earnings per share in € per ordinary share
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Operating income | -65 | -127 | -173 | -246 |
| EBITDA | -64 | -127 | -172 | -245 |
| Net income | -61 | -148 | -176 | -336 |
| Earnings per share | -3.18 | -3.43 | -2.80 | -4.83 |
| Balance sheet | ||||
| Total assets | 76 | 327 | 205 | 584 |
| Liabilities | 68 | 131 | 165 | 129 |
| Equity | 7.2 | 196 | 41 | 455 |
| Cash | 27 | 252 | 144 | 517 |
| Cash flow | ||||
| Operating cash flow | -54 | -97 | -154 | -161 |
| Capital expenditure | -0.3 | -0.3 | -0.6 | -0.1 |
| Free cash flow | -54 | -97 | -155 | -161 |
Annual returns
Best year 2025 at +1,742.3%, weakest 2024 at −31.6%. 1 of 2 full years were positive. * partial year.
Key metrics
Key figures as of 21 Nov 2026 from the company's latest annual financial report, amounts converted to US dollars at the ECB reference rate. Valuation and market cap appear only where price and earnings per share reliably refer to the same share.
Valuation
- Market cap
- €5.2bn
- Market cap in trading currency
- $5.70bn
- Enterprise value
- $5.13bn
- P/E
- –
- P/S
- –
- P/B
- 11.39
- EV/Sales
- –
- EV/EBITDA
- –
- Earnings yield
- –
- FCF yield
- -3.1%
Results (latest fiscal year)
- Revenue
- –
- Gross profit
- –
- EBITDA
- −$269m
- Net income
- −$369m
- Earnings per share
- −$5.31
- Revenue growth
- –
- Earnings growth
- –
Profitability
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity
- -135.6%
- Return on assets
- -57.5%
Balance sheet and cash flow
- Cash
- $568m
- Financial debt
- –
- Debt/equity %
- –
- Current ratio
- 8.75
- Book value per share
- $7.19
- Operating cash flow
- −$177m
- Free cash flow
- −$177m
Dividend
- Dividend yield
- 0.00%
- Dividend (12 months)
- $0.00
- Yield (12 months)
- 0.00%
- Payout ratio
- –
- Ex-dividend date
- –
Shares and trading
- Shares outstanding
- 69.6m
- Volume
- 14.8m
- Avg. volume 3 months
- 1.35m
- Relative volume
- 13.1
Price and technicals
- Price
- $73.20
- 1 day
- −9.2%
- 52-week high
- $145.31
- 52-week low
- $72.50
- Distance to 52-week high
- −49.6%
- Distance to 52-week low
- +1.0%
- Distance to 50-day line
- −19.7%
- Distance to 200-day line
- −34.5%
- RSI (14)
- 30
- Volatility 1M
- 54.7%
Performance
- 1 week
- −16.4%
- 1 month
- −18.9%
- 3 months
- −37.0%
- 6 months
- −40.0%
- YTD
- −45.7%
- 1 year
- −35.2%
Dates
- Fiscal year end
- 31 Dec 2025
Frequently asked questions
How has ABVX performed since 10/2023?
$10,000 grew to $88,193 by 20 Nov 2026, which is +102.5% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is ABVX?
Volatility was 479.4% per year, measured on monthly returns. The largest decline from a peak was −67.5%, with the low in 04/2025.
How does ABVX compare with a broad equity ETF?
Over the same period Global equities (VT) returned +17.7% per year at 12.8% volatility, ABVX returned +102.5% at 479.4%. The correlation of monthly returns was 0.01; 1 would mean they moved in lockstep.
Which currency are the figures in?
In US dollars, the currency of the US listing.
Why does this page show a US listing?
The figures use the stock's depositary receipt (ADR) traded in the US. On individual days its path differs slightly from the price on the home exchange.